NCT04258644Unknown2 期
Efficacy and Safety of Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- R0 resection rate
研究概览
简要总结
This is an interventional clinical trial to assess the efficacy and safety of camrelizumab in combination with apatinib mesylate, paclitaxel-albumin and S-1 for translational treatment of gastric cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •age:18～70; expected survival>3 months
- •pathologically diagnosed gastric cancer or esophageal-gastric-junction cancer, being predominantly adenocarcinoma
- •no previous treatment of anti-cancer drugs
- •ECOG score 0~2
- •CT/MRI/PET-CT diagnosed as unresectable
- •no disfunction of major organs
- •lab results satisfy the following criteria:
- •WBC≥3.5×109/L
- •Neutrophil≥1.5×109/L
- •Plt≥100×109/L
- •ALT、AST≤2.5 upper limit (≤5 upper limit for patients with liver metastasis)
- •Tbil≤1.5 upper limit
- •serum creatinine≤1.5 upper limit
- •7.women at child-bearing age must be tested negative within 7 days before inclusion, and must be willing to take contraception measures during treatment and within 12 weeks after last dose of treatment; men must be sterilized or willing to take contraception measures during treatment and within 12 weeks after last dose of treatment 8.willing to join this research with hand-signed written Informed consent 9.good compliance for follow-up
排除标准
- •patients with positive HER-2 test
- •with conditions that affect the absorption of oral drugs, such as inability to swallow, nausea and vomiting, chronic diarrhea and intestinal obstruction
- •allergic to carrizumab for injection, apatinib mesylate, paclitaxel for injection (albumin binding type) and tS-1 or relevant drug excipients; allergic to any other monoclonal antibodies; cannot tolerate radiation toxicity;
- •with active autoimmune disease or autoimmune disease history, such as interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism (can be included after hormone replacement therapy); patients with complete remission of childhood asthma and require no intervention can be included, whereas those who need medical intervention with bronchodilator cannot be included
- •with congenital or acquired immune defects, such as human immunodeficiency virus (HIV) infection, active hepatitis B (HBV DNA ≥ 500 IU / ml), hepatitis C (HCV antibody positive, and HCV-RNA higher than the lower detection limit of the analysis method) or combined hepatitis B and hepatitis C co infection
- •immunosuppressive drugs were used within 14 days before the first use of the study drug, excluding nasal spray and inhaled corticosteroids or systemic steroids in physiological dose (i.e. no more than 10 mg / day of prednisolone or other corticosteroids for equivalent amount);
- •inoculated live attenuated vaccine within 4 weeks before the first administration or during the study period
- •severe infection (requiring intravenous drip of antibiotics, antifungal or antiviral drugs) within 4 weeks before the first administration, or fever> 38.5° C of unknown cause during screening / before the first administration
- •known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation
- •objective evidence indicating previous or concurrent pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation-induced pneumonia, drug-related pneumonia, severe impairment of lung function, etc
- •patients with hypertension that cannot be restored to the normal range (systolic blood pressure ≤ 140 mmHg / diastolic blood pressure ≤ 90 mmHg) after treatment with antihypertensive drugs for 3 months
- •patients with uncontrolled clinical symptoms or diseases of the heart, including but not limited to congestive heart failure (NYHA grade > II); unstable or severe angina; acute myocardial infarction within 6 months; patients with clinically significant supraventricular or ventricular arrhythmia requiring clinical intervention; left ventricular ejection fraction (LVEF) < 50%
- •patients at risk of serious bleeding, including but not limited to severe bleeding (bleeding > 30 ml within 3 months), hemoptysis (bleeding > 5 ml within 4 weeks), and thromboembolism events (within the past 12 months)
- •with symptoms indicating Grade 2+ peripheral neuropathy
- •participating in other clinical trials, or participating in any clinical study for drugs within previous 4 weeks
- •other situations that the researchers regard as not suitable for inclusion.
研究组 & 干预措施
Camrelizumab+Apatinib+Paclitaxel-albumin+S-1
Experimental
Camrelizumab：D1, 200 mg ivgtt Apatinib Mesylate：D1~21, 250 mg, po qd Paclitaxel-albumin：D1&D8, 100～120 mg/m2 S-1：D1~14, 60mg bid
干预措施: Camrelizumab+Apatinib+Paclitaxel-albumin+S-1 (Drug)
结局指标
主要结局
R0 resection rate
时间窗: 3 years
proportion of patients for whom radical resection can be achieved
次要结局
- 3-year DFS(3 years)
- 1-year OS(1 year)
- PFS(3 years)
- OS(3 years)
- DFS(3 years)
- ORR(3 years)
- 3-year OS(3 years)
研究者
Zhongtao Zhang
Professor
Beijing Friendship Hospital
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Observational Study of Camrelizumab Combined With Apatinib and Hyperfractionated Radiotherapy for Renal Cell CarcinomaRenal Cell CarcinomaNCT04609293Peking University First Hospital30
终止
2 期
Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients with Recurrent Glioblastoma (GBM)Recurrent GlioblastomaNCT04952571Beijing Sanbo Brain Hospital3
Unknown
2 期
A Study to Evaluate Camrelizumab in Combination With Nb-Paclitaxel in Patients With Advanced or Metastatic NSCLCNon-Small Cell Lung CancerNCT04167774Sun Yat-sen University62
进行中（未招募）
1 期
Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.Esophageal NeoplasmImmunotherapyRadiotherapyNCT05176002Fujian Medical University Union Hospital25
Unknown
2 期
Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal CarcinomaNasopharyngeal CarcinomaNCT04547088Sun Yat-sen University27